CN111658624A - 树脂酸去氧肾上腺素颗粒 - Google Patents

树脂酸去氧肾上腺素颗粒 Download PDF

Info

Publication number
CN111658624A
CN111658624A CN202010471359.2A CN202010471359A CN111658624A CN 111658624 A CN111658624 A CN 111658624A CN 202010471359 A CN202010471359 A CN 202010471359A CN 111658624 A CN111658624 A CN 111658624A
Authority
CN
China
Prior art keywords
phenylephrine
drug
coated
coating
resin complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010471359.2A
Other languages
English (en)
Chinese (zh)
Inventor
D-Y.李
C.杰罗特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kolaqi Holdings Ltd
Sinango Zero Co ltd
Xinango Second Co ltd
Original Assignee
Johnson and Johnson Consumer Companies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Consumer Companies LLC filed Critical Johnson and Johnson Consumer Companies LLC
Publication of CN111658624A publication Critical patent/CN111658624A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202010471359.2A 2013-03-15 2014-02-28 树脂酸去氧肾上腺素颗粒 Pending CN111658624A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/832694 2013-03-15
US13/832,694 US20140271892A1 (en) 2013-03-15 2013-03-15 Phenylephrine resinate particles having good auc
CN201480015698.2A CN105263483A (zh) 2013-03-15 2014-02-28 树脂酸去氧肾上腺素颗粒

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480015698.2A Division CN105263483A (zh) 2013-03-15 2014-02-28 树脂酸去氧肾上腺素颗粒

Publications (1)

Publication Number Publication Date
CN111658624A true CN111658624A (zh) 2020-09-15

Family

ID=50272778

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010471359.2A Pending CN111658624A (zh) 2013-03-15 2014-02-28 树脂酸去氧肾上腺素颗粒
CN201480015698.2A Pending CN105263483A (zh) 2013-03-15 2014-02-28 树脂酸去氧肾上腺素颗粒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480015698.2A Pending CN105263483A (zh) 2013-03-15 2014-02-28 树脂酸去氧肾上腺素颗粒

Country Status (13)

Country Link
US (1) US20140271892A1 (https=)
EP (1) EP2968223B1 (https=)
JP (1) JP6314206B2 (https=)
CN (2) CN111658624A (https=)
AU (1) AU2014238059B2 (https=)
BR (1) BR112015022975B1 (https=)
CA (1) CA2906357C (https=)
IL (1) IL241050B (https=)
MX (1) MX383890B (https=)
PH (1) PH12015502066A1 (https=)
RU (1) RU2675788C2 (https=)
UA (1) UA116372C2 (https=)
WO (1) WO2014149526A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41152A (fr) * 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
CN109187832B (zh) * 2018-09-30 2021-07-30 华润三九医药股份有限公司 Lc-ms/ms测定去氧肾上腺素浓度的方法及样品的前处理方法
EP4271380A4 (en) * 2020-12-29 2025-01-22 Abbvie Inc. UPADACITINIB EXTENDED RELEASE FORMULATIONS
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294519A (zh) * 1999-02-18 2001-05-09 英法马有限公司 含有促进活性成分吸收活性的化合物的药物组合物
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20090047343A1 (en) * 2007-08-13 2009-02-19 Hugh Huang Method for stabilizing phenylephrine
CN101534795A (zh) * 2006-11-21 2009-09-16 麦克内尔-Ppc股份有限公司 改进释放的镇痛悬浮液
US20090324716A1 (en) * 2008-06-26 2009-12-31 Robert Shen Coated Particles Containing Pharmaceutically Active Agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429728A1 (en) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
CA2645855C (en) * 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US20080064694A1 (en) * 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
WO2010115015A1 (en) * 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
US20130230587A1 (en) * 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294519A (zh) * 1999-02-18 2001-05-09 英法马有限公司 含有促进活性成分吸收活性的化合物的药物组合物
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
CN101534795A (zh) * 2006-11-21 2009-09-16 麦克内尔-Ppc股份有限公司 改进释放的镇痛悬浮液
US20090047343A1 (en) * 2007-08-13 2009-02-19 Hugh Huang Method for stabilizing phenylephrine
US20090324716A1 (en) * 2008-06-26 2009-12-31 Robert Shen Coated Particles Containing Pharmaceutically Active Agents

Also Published As

Publication number Publication date
RU2015144181A (ru) 2017-04-21
RU2675788C2 (ru) 2018-12-25
WO2014149526A1 (en) 2014-09-25
IL241050B (en) 2018-07-31
CA2906357C (en) 2021-03-16
CN105263483A (zh) 2016-01-20
EP2968223B1 (en) 2020-10-28
MX2015012340A (es) 2016-06-29
BR112015022975B1 (pt) 2022-11-08
PH12015502066A1 (en) 2016-01-25
AU2014238059A1 (en) 2015-09-17
HK1219885A1 (en) 2017-04-21
JP2016512250A (ja) 2016-04-25
UA116372C2 (uk) 2018-03-12
AU2014238059B2 (en) 2019-01-03
JP6314206B2 (ja) 2018-04-18
CA2906357A1 (en) 2014-09-25
IL241050A0 (en) 2015-11-30
MX383890B (es) 2025-03-14
NZ712317A (en) 2020-09-25
US20140271892A1 (en) 2014-09-18
BR112015022975A8 (pt) 2022-07-26
BR112015022975A2 (pt) 2017-07-18
EP2968223A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
JP6314206B2 (ja) 樹脂酸フェニレフリン粒子
CN115068425A (zh) 制备去氧肾上腺素树脂酸盐颗粒的方法与去氧肾上腺素树脂酸盐颗粒及其在药剂中的用途
US20210322558A1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations
CN105246466B (zh) 带包衣的去氧肾上腺素颗粒及其在药物制剂中的用途
NZ712317B2 (en) Phenylephrine resinate particles
HK1219886B (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations
HK1219885B (en) Phenylephrine resinate particles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: New jersey, USA

Applicant after: JOHNSON & JOHNSON CONSUMER COMPANIES, Inc.

Address before: New jersey, USA

Applicant before: Kolaqi Holdings Ltd.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20220414

Address after: New jersey, USA

Applicant after: Kolaqi Holdings Ltd.

Address before: New jersey, USA

Applicant before: Xinango second Co.,Ltd.

Effective date of registration: 20220414

Address after: New jersey, USA

Applicant after: Xinango second Co.,Ltd.

Address before: New jersey, USA

Applicant before: Sinango zero Co.,Ltd.

Effective date of registration: 20220414

Address after: New jersey, USA

Applicant after: Sinango zero Co.,Ltd.

Address before: New jersey, USA

Applicant before: JOHNSON & JOHNSON CONSUMER COMPANIES, Inc.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20200915

RJ01 Rejection of invention patent application after publication